Investors

New Enterprise Associates (NEA)

NEA is one of the industry's premier venture capital firms. For 21 years, NEA has practiced classic venture capital by investing in early-stage companies and working with management to nurture and build companies of real and lasting value. NEA is now the leading start-up venture investor in the country. NEA shares characteristics with other venture firms but differs in many ways: its size and scope, the number of successful companies it has financed, its geographic reach, the experience and expertise of its partners and its commitment to its entrepreneurs and their companies. With $4.9 billion under management, NEA's experienced management team has invested in over 500 companies, of which more than 135 have gone public and more than 150 have been acquired. For additional information, visit www.nea.com.

Domain Associates, L.L.C.

Domain Associates is venture capital management company focused on life sciences. Domain was organized in 1985 to focus a group of senior partners with experience in relevant technologies on the many new venture opportunities evolving in life sciences. Domain's partners have been actively involved in the creation of venture capital-backed enterprises that now form the backbone of the biotechnology industry. Companies receiving early venture financing and active involvement from Domain's partners today account for over $100 billion of stock market value and over $5 billion in annual revenues. Portfolio investments include Amgen, Beansprout Networks, Inc., Dura Pharmaceuticals, Inc., iScribe, Inc., and U.S. Bioscience, Inc.   For more information go to www.domainvc.com.

Acacia Venture Partners

Acacia Venture Partners is a San Francisco-based venture capital firm specializing in identifying and building leading service businesses in healthcare and related industries. Acacia's venture capital professionals represent five decades of healthcare investing experience. The Fund's domain expertise ensures a deep understanding of these industries and enables it to offer access to a broad set of value-added resources. For more information go to www.acaciavp.com.

Quaker BioVentures

Quaker BioVentures is a venture capital firm dedicated to investing in life science companies located in the Mid-Atlantic region. The firm leads investments in companies across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, health information technology, and healthcare services. Quaker BioVentures invests in companies at varying stages of development, from early stage businesses to public companies. Quaker BioVentures manages approximately $280 million in capital. Funds under management include: Quaker BioVentures, L.P., Quaker BioVentures Tobacco Fund, L.P., Garden State Life Sciences Venture Fund, L.P., and BioAdvance Ventures, L.P. For more information go to www.quakerbio.com.

Montagu Newhall Associates

Montagu Newhall Associates is a leading venture capital fund of funds manager that invests in both top tier venture capital funds and high growth private companies. The Montagu Newhall partners have deep and extensive relationships with many of the leading venture capital firms in the industry, which they use to access high quality venture capital managers and private company opportunities. The firm has over $200 million under management and invests across the technology sector including information technology, communications and life sciences. For more information, go to www.montagunewhall.com.

Wasatch Advisors

Wasatch Advisors has been investing in small company stocks for nearly 30 years. The same people who built the track record are the portfolio managers today. It is the firm's philosophy that earnings growth drives stock prices over the long run. While small company stocks tend to be more risky and volatile, Wasatch believes they have the potential to grow faster, longer. In managing its portfolios, Wasatch focuses on finding investment opportunities through a research-intensive process of bottom-up, fundamental analysis that includes visiting over 800 companies a year and meeting with senior management. Wasatch is committed to maintaining style consistency through the disciplined pursuit of each portfolio's investment strategies. Part of that discipline includes closing portfolios that invest in small companies in an effort to control asset size and avoid hindering performance. For more information, visit www.wasatchadvisors.com.